Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 227-237

  Abrogoua, Danho Pascal ^a,b   Kablan, Brou Jerome ^a   Thierry Kamenan, Boua Alexis ^a,b   Aulagner, Gilles ^c   N'Guessan, Konan ^a   Zohoré, Christian ^a  

^a UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^b CHU de Cocody   (Côte d’Ivoire)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Abidjan; Adherence; Antiretroviral therapy; CD4 cells response; Modeling; Predictors

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; FEMALE; FOLLOW UP; HEALTH STATUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONITORING; OUTPATIENT; PATIENT COMPLIANCE; PROBABILITY;

EID: 84886065533     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S26507     Document Type: Article

References (76)

1. Joint United Nations Program on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. November 2010. Available from: http://www.unaids.org/documents/20101123_GlobalReport_ Foreword_em.pdf. Accessed February 23, 2012.
2. Gadelha AJ, Accacio N, Costa RL, et al. Morbidity and survival in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2002;44(4):179-186.
3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). 2006. Available from: http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. Accessed February 23, 2012.
4. Yeni P. 2008 report of the expert group on the medical management of people infected with HIV: recommendations. August 19, 2008. Available from: http://www.sante.gouv.fr/rapport-du-groupe-d-experts-2008-surla-prise-en-charge-medicale-des-patients-infectees-par-le-vih-sousla-direction-du-pr-patrick-yeni.html. Accessed February 23, 2012. French.
5. Dray-Spira R, Spire B, Heard I, Lert F. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. AIDS. 2007;21 Suppl 1:S5-S12.
6. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. Available from: http://s-cap.org/documents/GuidlinesforAntiretrovialTher apy12-11-09.pdf. Accessed February 23, 2012.
7. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med. 2003;163(18):2187-2195.
8. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005;39(2): 195-198.
9. Garcia F, de Lazzari E, Plana M, et al. Long-term CD4T-cell response to highly active antiretroviral therapy according to baseline CD4T-cell count. J Acquir Immune Defic Syndr. 2004;36(2):702-713.
10. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-129.
11. Teerawattananon Y, Hanshaoworakul W, Russell S, Tangcharoensathien V, Jiamton S. Targeting antiretroviral therapy: lessons from a longitudinal study of morbidity and treatment in relation to CD4 count in Thailand. Asia Pac J Public Health. 2006;18(1):39-48.
12. Wood E, Hogg RS, Harrigan PR, Montaner JSG. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5(7):407-414.
13. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286(20):2568-2577.
14. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-1363.
15. Baker JV, Peng G, Rapkin J, et al. CD4count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22(7): 841-848.
16. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4cell strata. Ann Intern Med. 2003;138(8):620-626.
17. Cameron DW, Heath-Chiozzi M, Danner S, et al; Advanced HIV Disease Ritonavir Study Group. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet. 1998;351(9102):543-549.
18. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-366.
19. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002;360(9326):34-40.
20. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285-297.
21. Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS. 2004;18(15): 2029-2038.
22. Abrogoua DP, Aulagner G, Kablan BJ, Petit C. Study of meta-trajectories of CD4 cells count from taxonomy in the antiretroviral response of efavirenz-based regimen with naive symptomatic patients in Abidjan. Ann Pharm Fr. 2011;69(1):7-21. French.
23. Abrogoua DP, Kablan BJ, Aulagner G, Petit C. Modeling of antiretroviral response from taxonomy of CD4 cells count trajectories in profound immunodeficiency setting. Therapie. 2011;66(3):247-261. French.
24. Abrogoua DP, Kablan BJ, Aulagner G, Petit C. Modeling of nevirapine-based antiretroviral regimen response by taxonomy from different CD4 cell counts strata. Afr J Pharm Pharmacol. 2011;5(7): 930-942.
25. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(5):553-558.
26. van Griensven J, Zachariah R, Rasschaert F, Reid T. Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr. 2009;50(5):556-558.
27. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS. 2006;20(3):371-377.
28. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr. 2005;40(3):288-293.
29. Achhra AC, Amin J, Law MG, et al. Immunodefi{ligature}ciency and the risk of serious clinical endpoints in a well studied cohort of treated HIVinfected patients. AIDS. 2010;24(12):1877-1886.
30. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:(RR-17):1-19.
31. Eholie SP, Girard PM. Therapeutic memento of HIV/AIDS in Africa. Paris, France: Doin; 2005. French.
32. Eholie SP, Tanon KA, Folquet-Amorissani M, et al. Impact of access to antiretroviral therapy in Cote d'Ivoire. Med Trop (Mars). 2009;69(5):520-524. French.
33. Wolbers M, Battegay M, Hirschel B, et al. CD4T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antivir Ther. 2007;12(6):889-897.
34. Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4() cell counts in human immunodeficiency virusinfected patients receiving a protease inhibitor containing antiretroviral regimen. J Infect Dis. 2002;185(4):471-480.
35. Tarwater PM, Margolick JB, Jin J, et al. Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(2):168-175.
36. Lawn SD, Myer L, Bekker LG, Wood R. CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis. 2006;6:59.
37. Nakanjako D, Kiragga A, Ibrahim F, Castelnuovo B, Kamya MR, Easterbrook PJ. Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther. 2008;5:23-31.
38. Kitahata M, Dillingham P, van Rompaey S. Initiating potent combination antiretroviral therapy within 1 year of the first clinic visit for patients at all CD4 cell count levels is associated with better longterm outcomes. Paper presented at: 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, WA. Poster 467.
39. Sterne JA, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366(9483):378-384.
40. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19(18): 2141-2148.
41. Moore RD, Keruly JC. CD4cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44(3):441-446.
42. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133(6):401-410.
43. Tuboi SH, Brinkhof MW, Egger M, et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr. 2007;45(1):52-59.
44. Hazenberg MD, Otto SA, van Benthem BH, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17(13):1881-1888.
45. Eggena MP, Barugahare B, Okello M, et al. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4T cell depletion, and coinfection. J Infect Dis. 2005;191(5): 694-701.
46. Borkow G, Weisman Z, Leng Q, et al. Helminths, human immunodeficiency virus and tuberculosis. Scand J Infect Dis. 2001;33(8): 568-571.
47. Delgado J, Heath KV, Yip B, et al. Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill. Antivir Ther. 2003;8(5):471-478.
48. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8(3):261-269.
49. Gordillo V, del Amo J, Soriano V, Gonzalez-Lahoz J. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999;13(13):1763-1769.
50. Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS. 1999;13(9):1099-1107.
51. Dragsted UB, Mocroft A, Vella S, et al. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis. 2004;190(1):148-155.
52. Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16(2):201-207.
53. Wu H, Connick E, Kuritzkes DR, et al. Multiple CD4cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001;17(13):1231-1240.
54. Hill A, Montaner J, Lederman M, Cuttrell A, Tortell S, Thorborn D. Discordant CD4/RNA responses to HAART are strongly associated with high baseline CD4 count and low HIV RNA: analysis of 406 naive patients. Paper presented at: 3rd International Workshop on Drug Resistance and Treatment Strategies; June 23-26; San Diego, CA. Poster 152.
55. Kulkarni H, Okulicz JF, Grandits G, et al. Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2011;57(5):387-395.
56. Montaner JS, Hogg R, Raboud J, Harrigan R, O'Shaughnessy M. Antiretroviral treatment in 1998. Lancet. 1998;352(9144):1919-1922.
57. Moreno A, Perez-Elias MJ, Casado JL, et al. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice. Antivir Ther. 2000;5(4):243-248.
58. Eholie SP. Analysis of adherence to antiretroviral therapy in Abidjan. Paper presented at: 13th International Conference of HIV/AIDS and Sexually Transmitted Infections in Africa; September 22-25, 2003; Nairobi, Kenya. Abstract 971451. French.
59. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369-1375.
60. Tassie JM, Szumilin E, Calmy A, Goemaere E; Medecins Sans Frontieres. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS. 2003;17(13):1995-1997.
61. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and it principal determinants in a cohort of Senegalese adults. AIDS. 2003;17 Suppl 3:S103-S108.
62. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053-1056.
63. Daniel OJ, Ogun SA, Odusoga OL, et al. Adherence pattern to ARV drugs among AIDS patients on self-purchased drugs and those on free medications in Sagamu, Nigeria. Paper presented at: The XV International AIDS Conference; March 30-April 2, 2004; Bangkok, Thailand. Abstract WePeB5768.
64. Eholie SP, Tanon A, Polneau S, et al. Field adherence to highly active antiretroviral therapy in HIV-infected adults in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2007;45(3):355-358.
65. Lifson AR, Krantz EM, Eberly LE, et al. Long-term CD4lymphocyte response following HAART initiation in a US Military prospective cohort. AIDS Res Ther. 2011;8(1):2.
66. Patterson K, Napravnik S, Eron J, Keruly J, Moore R. Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy. HIV Med. 2007;8(6):406-410.
67. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged 50 years compared with younger people in an urban observational cohort. Clin Infect Dis. 2003;36(2): 212-218.
68. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS. 2001;15(14):1749-1756.
69. Aiuti F, Mezzaroma I. Failure to reconstitute CD4T-cells despite suppression of HIV replication under HAART. AIDS Rev. 2006;8(2): 88-97.
70. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396(6712):690-695.
71. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood. 2002;99(10):3702-3706.
72. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17(13):1907-1915.
73. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to,500 cells/L in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361-372.
74. Mocroft A, Phillips AN, Ledergerber B, et al. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006;20(8): 1141-1150.
75. Le Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients treated with a plasma HIV RNA persistently,500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8(3):156-163.
76. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183(8):1290-1294.